Every Form 4 that Aurinia Pharmaceuticals Inc (AUPH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AUPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AUPH filings page.
Aurinia Pharmaceuticals Inc. (AUPH) reported that Chief Legal Officer Stephen P. Robertson sold 11,939 shares of common stock on September 10, 2026 at a weighted average price of about $15.95 per share, with trades between $15.95 and $15.96. The shares were automatically sold solely to cover tax withholding obligations arising from the vesting of Performance Stock Units related to a February 28, 2025 performance award, and Robertson now holds 588,848 shares directly.
Aurinia Pharmaceuticals Inc. (AUPH) reported that Chief Legal Officer Stephen P. Robertson sold 20,975 shares of common stock on August 21, 2026 in a sale in the open market or a private transaction at a weighted average price of $16.97 per share. According to the company’s disclosure, these shares were automatically sold to cover tax withholding obligations arising from the vesting of Performance Stock Units related to a February 28, 2025 performance award. After this tax-related sale and including 360 shares acquired on May 29, 2026 under the 2021 Employee Share Purchase Plan, Robertson beneficially holds 600,787 common shares directly.
Aurinia Pharmaceuticals Inc. director Craig A. Johnson received a grant of stock options as part of his compensation. He was awarded 23,931 Director Stock Options, each giving the right to buy one common share at an exercise price of $15.67 per share.
The options vest one year from the grant date and expire on June 4, 2036. Following this grant, Johnson holds 23,931 options directly, with no open-market buying or selling reported in this filing.
Aurinia Pharmaceuticals director Kathleen Goetz received a grant of 23,931 Director Stock Options on June 4, 2026. These options give her the right to buy an equal number of common shares at an exercise price of 15.67 per share and expire on June 4, 2036.
The options were granted as compensation, not purchased in the market, and vest one year from the date of grant. Following this award, her reported derivative holdings from this grant total 23,931 options, all held directly.
Aurinia Pharmaceuticals Inc. reported that director Tina Susan Nova received a grant of stock options. The award covers 23,931 options to purchase common shares at an exercise price of $15.67 per share and is treated as a compensation grant, not a market purchase.
The options vest in full one year from the grant date and expire on June 4, 2036. Following this grant, Nova holds 23,931 derivative securities directly in the form of these options.
Aurinia Pharmaceuticals Inc. director Jeffrey Allen Bailey received a grant of stock options as part of his compensation. The award covers 23,931 options to purchase common shares at an exercise price of $15.67 per share. These options vest one year from the grant date and expire on June 4, 2036. Following this grant, Bailey holds 23,931 options directly, with no open-market purchases or sales reported in this filing.
Aurinia Pharmaceuticals Inc. insider entities associated with Chief Executive Officer Kevin Tang reported significant open-market buying of common shares and new derivative positions. Funds managed through Tang Capital partnerships bought a net 814,606 common shares in late May and early June at prices around $15 per share, bringing their indirect holdings to 13,044,106 shares.
In a separate move, Tang-affiliated funds sold 10,000 short put options, creating a potential obligation to acquire up to 1,000,000 additional common shares at $15 per share if exercised by January 15, 2027. Together, these transactions increase the funds’ equity exposure to Aurinia while adding conditional future buying commitments.
Robertson Stephen P. reported acquisition or exercise transactions in this Form 4 filing.
Aurinia Pharmaceuticals Inc. reported that its Chief Legal Officer, Stephen P. Robertson, received an equity compensation award in the form of 115,541 performance stock units. These units were granted at no cash cost per unit and increase his direct holdings to 621,402 common shares or share-based units reported in this filing.
The footnote explains that each performance stock unit represents a contingent right to receive one common share of Aurinia. The 115,541 units vest in two tranches on the third and fifth anniversaries of the grant date, only if Aurinia’s common shares reach target prices that represent significant increases from the grant-date share price before each vesting date.
Hearne Michael S reported acquisition or exercise transactions in this Form 4 filing.
Aurinia Pharmaceuticals Inc. reported that Chief Financial Officer Michael S. Hearne received new equity compensation awards. He was granted 116,144 performance stock units, each representing a contingent right to receive one common share, and 70,230 employee stock options.
The PSUs vest in multiple tranches based on Aurinia’s share price performance and time-based conditions, while the options have a strike price of $15.28 per share and expire on May 18, 2036. These are compensation-related grants rather than open-market share purchases or sales.
Aurinia Pharmaceuticals Inc. reported that Chief Operating Officer Ryan Cole received new equity awards. He was granted 116,144 performance stock units, each representing a contingent right to receive one common share, with vesting tied to share-price targets and time-based conditions. He also received an option grant for 70,230 shares of common stock at an exercise price of $15.28 per share, expiring in 2036. These awards are compensation-related grants, and no open-market share purchases or sales were reported in this filing.
Aurinia Pharmaceuticals Inc. reported that SVP and Chief Medical Officer Greg Keenan had 8,069 shares of Common Stock withheld on March 6, 2026 to cover tax obligations when restricted stock units vested. These shares were valued at $14.32 per share for this tax-withholding calculation. After this routine withholding, Keenan directly holds 154,449 common shares, showing he maintains a substantial equity position in the company.
Aurinia Pharmaceuticals Inc. director-associated entities reported significant open-market purchases of common shares. Limited partnerships associated with Kevin Tang bought a total of 900,000 common shares of Aurinia between February 27 and March 3, 2026, in a series of indirect transactions labeled “By LP.”
The purchases were executed at weighted-average prices around the mid-teens per share, with footnotes stating that the trades occurred in multiple transactions within ranges such as $13.51–$14.23 and several other bands in the low-to-mid $14 area. Following these buys, entities associated with Tang were reported as beneficially owning over 12 million Aurinia common shares.
Aurinia Pharmaceuticals Inc. reported insider equity activity by Chief Financial Officer Joseph M. Miller. On February 27, 2026, he received a grant of 95,700 employee stock options with an exercise price of $0.0000 per share and an award of 57,229 shares of common stock at no cost. The options vest one-third after twelve months from the grant date, with the remaining two-thirds vesting in twenty-four equal monthly installments.
Each performance right associated with these awards represents a contingent right to receive one common share, vesting in four tranches as the share price reaches progressively higher targets, each with a one-year retention period. On March 2, 2026, 37,511 common shares at $14.21 per share were withheld as a tax-withholding disposition to satisfy tax obligations upon vesting of restricted stock units, leaving Miller with 576,421 directly held common shares.
Aurinia Pharmaceuticals Inc. Chief Operating Officer Matthew Maxwell Donley reported equity compensation and related tax withholding transactions. On February 27, 2026, he received a grant of 97,256 employee stock options at an exercise price of $0.00 per share and a grant of 58,160 shares of common stock at no cost, both held directly.
Following the stock award, his directly held common stock position increased to 721,060 shares. On March 2, 2026, 40,761 common shares valued at $14.21 per share were disposed of through a tax-withholding disposition to satisfy tax obligations upon vesting of restricted stock units, leaving 680,299 common shares held directly.
Aurinia Pharmaceuticals Inc. reported insider equity activity by Chief Executive Officer Peter Greenleaf. He received a grant of 328,424 employee stock options at an exercise price of $0.0000 per share, with one-third vesting twelve months from the grant date and the remainder vesting in twenty-four equal monthly installments thereafter.
On the same grant date, he also acquired 196,403 shares of common stock through an award. Separately, 100,890 common shares were disposed of to cover tax withholding obligations upon the vesting of restricted stock units. Following these transactions, he directly owned 1,840,379 common shares.
Aurinia Pharmaceuticals Inc. reported that SVP and Chief Medical Officer Greg Keenan received new equity awards on February 27, 2026. He was granted stock options for 67,870 shares at an exercise price of $0, increasing his option holdings to 67,870 shares.
He also acquired 40,586 shares of common stock as a grant or award at a stated price of $0, bringing his directly held common shares to 162,518. Footnotes explain that related performance rights vest in tranches based on share price targets and time-based vesting schedules.
Aurinia Pharmaceuticals Inc. executive vice president and general counsel Stephen P. Robertson reported multiple equity transactions. On February 27, 2026, he received a grant of 98,813 employee stock options with a $0 exercise price and a separate award of 59,090 common shares, both held directly.
On March 2, 2026, 36,525 common shares were disposed of to satisfy tax withholding obligations upon vesting of restricted stock units, at a price of $14.21 per share. After these transactions, he directly owned 505,861 common shares.
Aurinia Pharmaceuticals Inc. insider activity: Chief Operating Officer Matthew Maxwell Donley reported a tax-related share disposition tied to equity compensation. On this Form 4, 32,901 shares of common stock were withheld at $14.4000 per share to satisfy tax obligations upon the vesting of restricted stock units. This was an automatic tax-withholding disposition, not an open-market trade, and Donley continued to hold 662,900 common shares directly after the transaction.
Aurinia Pharmaceuticals Inc. Chief Executive Officer Peter Greenleaf reported a Form 4 transaction involving company common stock. On February 20, 2026, 100,171 shares were disposed of at $14.40 per share in a tax-withholding disposition, meaning shares were withheld to cover tax obligations upon vesting of restricted stock units rather than sold in an open-market trade. After this transaction, Greenleaf directly owned 1,744,866 common shares.
Aurinia Pharmaceuticals Inc. Chief Financial Officer Joseph M. Miller reported a tax-related share disposition. On the vesting of restricted stock units, 32,424 shares of common stock were withheld at $14.40 per share to cover tax obligations, according to the footnote. After this withholding transaction, Miller directly owned 556,703 common shares.
Aurinia Pharmaceuticals Inc.'s EVP and General Counsel, Stephen P. Robertson, reported a Form 4 transaction involving company common stock. On February 20, 2026, 34,638 shares of common stock at $14.40 per share were disposed of to satisfy tax withholding obligations tied to vesting restricted stock units, rather than through an open-market sale. After this tax-withholding disposition, Robertson’s directly held ownership stood at 483,296 common shares.
Aurinia Pharmaceuticals senior vice president and chief medical officer Greg Keenan reported a routine share withholding tied to equity compensation. On 02/02/2026, 11,552 shares of common stock were withheld at $14.53 per share to satisfy tax obligations when restricted stock units vested.
After this tax-related withholding, Keenan beneficially owns 121,932 shares of Aurinia common stock, held directly. The filing reflects an administrative adjustment rather than an open-market purchase or sale, and confirms his ongoing equity stake in the company.
Aurinia Pharmaceuticals Inc. (AUPH) filed a Form 4 reporting a tax-related share withholding by a director. On 11/21/2025, a director had 2,716 common shares withheld at a price of $15.68 per share to cover tax obligations when restricted stock units vested. This was recorded as a disposition of shares for tax purposes, not an open-market sale. After this transaction, the director beneficially owns 22,775 common shares, held directly.
The filing clarifies that the reported transaction represents shares withheld to satisfy tax withholding obligations upon RSU vesting, which is a common administrative equity compensation event for insiders.
Aurinia Pharmaceuticals Inc. (AUPH) reported an insider equity transaction on a Form 4 involving one director. On 11/21/2025, the director had 6,039 common shares withheld at a price of $15.68 per share to cover tax withholding obligations tied to the vesting of restricted stock units. After this tax-related withholding, the director directly beneficially owned 14,592 common shares of Aurinia. This event reflects routine equity compensation and tax management rather than an open-market purchase or sale.